| Pharmaceutical Information |
| Drug Name |
Besifloxacin |
| Drug ID |
BADD_D00256 |
| Description |
Besifloxacin is a fourth generation fluoroquinolone-type opthalmic antibiotic for the treatment of bacterial conjunctivitis. FDA approved on May 28, 2009. |
| Indications and Usage |
Treatment of bacterial conjunctivitis. Bacterial isolates that are susceptible to besifloxacin include: CDC coryneform group G; Corynebacterium pseudodiphtheriticum; Corynebacterium striatum; Haemophilus influenzae; Moraxella lacunata; Staphylococcus aureus; Staphylococcus epidermidis; Staphylococcus hominis; Staphylococcus lugdunensis; Streptococcus mitis group; Streptococcus oralis; Streptococcus pneumoniae; Streptococcus salivarius* |
| Marketing Status |
approved |
| ATC Code |
S01AE08 |
| DrugBank ID |
DB06771
|
| KEGG ID |
D08872
|
| MeSH ID |
C522124
|
| PubChem ID |
10178705
|
| TTD Drug ID |
D00TRV
|
| NDC Product Code |
24208-446 |
| UNII |
BFE2NBZ7NX
|
| Synonyms |
besifloxacin | 7-(3-aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid | besivance | besifloxacin hydrochloride | BOL-303224-A | 7-((3R)-aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid |
|
| Chemical Information |
| Molecular Formula |
C19H21ClFN3O3 |
| CAS Registry Number |
141388-76-3 |
| SMILES |
C1CCN(CC(C1)N)C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4CC4)F |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
